Recombinant Virus Vector for Endogenous Cetuximab-like Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody protein therapies for treating dysregulated EGFR-related cancers require intravenous administration, which is costly, disruptive to patients' lives, and poses a risk of healthcare-acquired nosocomial infections.
Innovation Solution
The development of compositions and methods that induce a subject to produce a Cetuximab-like protein (CLP) endogenously, which binds to and inhibits Epidermal Growth Factor Receptor (EGFR), thereby reducing excessive DNA synthesis and tumor cell growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous administration of monoclonal antibody protein therapies is used, then cancer treatment efficacy is achieved, but patient disruption and infection risk increase
Solution Approach 1:
The patent applies the self-service principle by enabling the patient's own body to produce the therapeutic monoclonal antibody through gene therapy. The recombinant virus vector delivers the antibody-encoding gene to the patient's cells, allowing the patient's cells to manufacture and secrete the therapeutic CLP autonomously, eliminating the need for continuous external administration and reducing dependency on healthcare systems.
Solution Approach 2:
The patent uses a recombinant virus vector as an intermediary to deliver the therapeutic gene into the patient's cells. The virus vector serves as a carrier that facilitates the transfer of the monoclonal antibody-encoding gene from the laboratory to the patient's target cells, enabling endogenous production without requiring direct intravenous administration of the antibody itself.
2Reliability
If intravenous administration of monoclonal antibody protein therapies is used, then cancer treatment is provided, but cost and administration complexity increase
Solution Approach 1:
The therapy transitions from requiring complex external administration systems to utilizing the patient's own cellular machinery. Once the gene is delivered via virus vector, the patient's cells automatically produce, process, and secret the therapeutic antibody through their normal protein synthesis pathways, eliminating the need for ongoing intravenous infusion equipment and administrative overhead.
Solution Approach 2:
The patent applies preliminary action by delivering the gene-encoding sequence to the patient's cells before the actual therapeutic effect is needed. The recombinant virus vector establishes the genetic machinery in advance, allowing the patient's cells to produce the therapeutic CLP continuously over time without requiring repeated administration procedures.
3Reliability
If exogenous monoclonal antibody administration is used, then EGFR inhibition is achieved, but continuous external intervention is required
Solution Approach 1:
The therapy transforms from a externally-controlled system to an internally-sustained system. The patient's cells, now containing the monoclonal antibody-encoding gene, continuously produce and secrete the therapeutic CLP autonomously, maintaining EGFR inhibition without requiring external intervention. This self-sustaining production can continue as long as the patient's cells remain viable and express the transgene.
Solution Approach 2:
The patent achieves continuous useful action by establishing a permanent genetic modification in the patient's cells that enables ongoing endogenous production of the therapeutic antibody. Unlike transient external administration, the gene therapy creates a lasting capability for continuous CLP secretion, maintaining EGFR inhibition throughout the patient's life or until disease progression occurs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The endogenous production of CLP provides a targeted therapy for cancer, offering bioavailability and functional equivalence to exogenously administered Cetuximab, potentially reducing the risks and disruptions associated with traditional therapies.
Implementation Method 1
The insert sequence is expressed and/or replicated. Expression of the insert sequence by one or more cells of the subject results in an increased production of the CLP by the subject.
Implementation Method 2
the mAB binds to and inhibits Epidermanl Growth Factor Receptor (EGFR) by binding to the extracellular ligand-binding domain of EGFR. This mAB binding blocks the EGFR's ability to bind other stimulatory ligands
Implementation Method 3
it may reduce excessive deoxyribonucleic acid (DNA) synthesis in tumor cells and, therefore, growth and proliferation of the tumor cells.
Data Source
AI summary
The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a Cetuximab-like protein (CLP) by a subject that is administered the agent, therapy or treatment. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition that may benefit from reducing the DNA synthesis of genes that regulate cellular growth and proliferation.